FAIM
TGTX icon

Financial Advocates Investment Management’s TG Therapeutics TGTX Stock Holding History

Financial Advocates Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,423
Closed -$210K – 802
2021
Q2 		$210K Sell
5,423
-9
-0.2% -$353 0.01% 695
2021
Q1 		$262K Hold
5,432
– – 0.02% 647
2020
Q4 		$283K Buy
+5,432
New +$184K 0.02% 581

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Advocates Investment Management's TGTX Position: Q3 2021 in Review

Financial Advocates Investment Management sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 5,423 shares — an estimated $210K sold.

Financial Advocates Investment Management first reported a position in TGTX in Q4 2020 and held it in 3 quarters. The position peaked at $283K in Q4 2020. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • Financial Advocates Investment Management reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Financial Advocates Investment Management sold 5,423 TG Therapeutics shares in Q3 2021, an estimated $210K.
  • Financial Advocates Investment Management first reported a position in TG Therapeutics in Q4 2020 and held it in 3 quarters.
  • Financial Advocates Investment Management's TG Therapeutics position peaked at $283K in Q4 2020.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Financial Advocates Investment Management's 13F filing for Q3 2021, filed 4 Nov 2021.